The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The Adipocyte and Hemostatic Balance in Obesity: Studies of PAI-1
Abstract
HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 18, No. 1The Adipocyte and Hemostatic Balance in Obesity Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessOtherPDF/EPUBThe Adipocyte and Hemostatic Balance in Obesity Studies of PAI-1 David J. Loskutoff and Fahumiya Samad David J. LoskutoffDavid J. Loskutoff From the Department of Vascular Biology, The Scripps Research Institute, La Jolla, Calif. and Fahumiya SamadFahumiya Samad From the Department of Vascular Biology, The Scripps Research Institute, La Jolla, Calif. Originally published1 Jan 1998https://doi.org/10.1161/01.ATV.18.1.1Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18:1–6Plasminogen activator inhibitor 1 is the primary physiological inhibitor of plasminogen activation in vivo, and elevations in plasma PAI-1 appear to compromise normal fibrin clearance mechanisms and promote thrombosis. PAI-1 is dramatically upregulated in obesity, a complex condition associated with increased risk for myocardial infarction, accelerated atherosclerosis, hypertension, glucose intolerance, insulin resistance, hyperinsulinemia, and NIDDM. In spite of the apparent link between elevated PAI-1 levels and thrombotic disease, little is known about the origin of this plasma inhibitor in obesity/NIDDM or about the signals that control its biosynthesis. Potential insights into the underlying molecular events have come from recent studies of genetically obese mice and of cultured adipocytes. These studies are reviewed here.* They emphasize the key role played by the adipocyte, a cell whose numbers, size, and metabolic activity are grossly altered in obesity/NIDDM. They also suggest that multiple cytokines, hormones, and growth factors may be involved, and they raise the possibility that the abnormal expression of other hemostatic genes by adipocytes in obesity/NIDDM may also contribute to the cardiovascular complications of this disorder. In this regard, our preliminary studies indicate that TF gene expression is elevated in the adipose tissues of the obese mouse.Properties of PAI-1PAI-1 appears to be the primary physiological inhibitor of plasminogen activation in blood, since it is the only PAI found complexed with single-chain tissue-type PA in carefully collected human plasma, and the second-order rate constant for its interaction with tissue-type PA and urokinase-type PA (≈3.5×107 [mol/L] −1 · s−1) is at least two orders of magnitude higher than that of other PAIs.1234 The normal concentration of PAI-1 protein in human plasma ranges from 6 to 80 ng/mL with a geometric mean at 24 ng/mL, whereas that of tissue-type PA is 5 to 10 ng/mL. Abnormalities in the concentration of PAI-1 are frequently associated with vascular disease. For example, the inhibitor is elevated in a variety of thrombotic conditions, including myocardial infarction and deep venous thrombosis. Elevated PAI-1 also correlates with thrombosis in animal models, and transgenic mice that overexpress PAI-1 have been reported to develop venous thrombosis.5 On the other hand, the absence of PAI-1 in humans leads to life-long bleeding problems presumably resulting from the development of a hyperfibrinolytic state, and disruption of the PAI-1 gene in mice is also associated with a mild hyperfibrinolytic state as manifested by increased resistance to endotoxin-induced thrombosis.5 Finally, neutralizing plasma PAI-1 activity with specific antibodies or by the use of PAI-1 inhibitors46 enhances spontaneous or tissue-type PA–mediated thrombolysis. These observations emphasize that imbalances in the PA/PAI-1 ratio are likely to promote either thrombosis or bleeding. As summarized in the next section, this balance is severely disturbed in obesity/NIDDM.PAI-1 itself is a single-chain glycoprotein (13% carbohydrate) of ≈Mr 50 000 and consists of 379 amino acids, although some amino-terminal heterogeneity has been reported. It lacks cysteines but contains multiple methionines, which may account for its susceptibility to irreversible inactivation by oxidizing agents. The reactive center of the inhibitor (Arg346/Met347) is contained within the exposed "strained loop" region at the carboxy terminus of the molecule and serves as a pseudosubstrate for the target serine protease. Inhibition of PAs by PAI-1 occurs in a rapid and stoichiometric manner, resulting in the formation of a covalent bond between the two molecules. The inhibitor is consumed in the process, giving rise to the term "suicide inhibitor." PAI-1 is ≈30% homologous with α1-antitrypsin and antithrombin III and is thus a member of the serine protease inhibitor (serpin) superfamily. The general structure of active PAI-1 is similar to that of other serpins, since it appears to be in a stressed conformation that is sensitive to thermal denaturation. The human PAI-1 gene is ≈12.2 kbp long, is organized into 9
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adipogenesis and Obesity: Rounding Out the Big Picture
Spiegelman, B. M., & Flier, J. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81359-8 · Cited by 1,269
Plasminogen activator inhibitors
Sprengers, E., & Kluft, C. (1987) · Blood · doi:10.1182/blood.v69.2.381.381 · Cited by 1,009
Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty
Shimomura, I., Funahasm, T., Takahashi, M., Maeda, K., Kotani, K., Nakamura, T., Yamashita, S., Miura, M., Fukuda, Y., Takemura, K., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-800 · Cited by 890
MEADE, T. (1993) · The Lancet · doi:10.1016/0140-6736(93)92062-x · Cited by 711
Alessi, M. C., Peiretti, F., Morange, P., Henry, M., Nalbone, G., & Juhan-Vague, I. (1997) · Diabetes · doi:10.2337/diab.46.5.860 · Cited by 615
Sharma, K., & Ziyadeh, F. N. (1995) · Diabetes · doi:10.2337/diab.44.10.1139 · Cited by 554
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Sawdey, M. S., & Loskutoff, D. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115440 · Cited by 410
Self-citationRidker, P. M., Gaboury, C. L., Conlin, P. R., Seely, E. W., Williams, G. H., & Vaughan, D. E. (1993) · Circulation · doi:10.1161/01.cir.87.6.1969 · Cited by 400
PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events
Juhan-Vague, I., & Alessi, M. C. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657607 · Cited by 384
Cited by
Adipose Tissue, Inflammation, and Cardiovascular Disease
Berg, A. H., & Scherer, P. E. (2005) · Circulation Research · doi:10.1161/01.res.0000163635.62927.34 · Cited by 2,113
Monocyte chemoattractant protein 1 in obesity and insulin resistance
Sartipy, P., & Loskutoff, D. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133870100 · Cited by 1,201
Self-citationAdipokines: molecular links between obesity and atheroslcerosis
Lau, D. C. W., Dhillon, B., Yan, H., Szmitko, P. E., & Verma, S. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01058.2004 · Cited by 931
Adipose tissue in control of metabolism
Luo, L., & Liu, M. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0211 · Cited by 693
Leptin induces oxidative stress in human endothelial cells
Bouloumié, A., Marumo, T., Lafontan, M., & Busse, R. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.10.1231 · Cited by 679
Vesely, S. K., George, J. N., Lämmle, B., Studt, J.-D., Alberio, L., El-Harake, M. A., & Raskob, G. E. (2003) · Blood · doi:10.1182/blood-2003-01-0193 · Cited by 676
Combs, T. P., Berg, A. H., Rajala, M. W., Klebanov, S., Iyengar, P., Jimenez-Chillaron, J. C., Patti, M. E., Klein, S. L., Weinstein, R. S., & Scherer, P. E. (2003) · Diabetes · doi:10.2337/diabetes.52.2.268 · Cited by 544
Stentz, F. B., Umpierrez, G. E., Cuervo, R., & Kitabchi, A. E. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2079 · Cited by 497
The Hyperglycemia-induced Inflammatory Response in Adipocytes
Lin, Y., Berg, A. H., Iyengar, P., Lam, T. K. T., Giacca, A., Combs, T. P., Rajala, M. W., Du, X., Rollman, B., Li, W., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411863200 · Cited by 497
Cottam, D. R., Mattar, S. G., Barinas-Mitchell, E., Eid, G., Kuller, L., Kelley, D. E., & Schauer, P. R. (2004) · Obesity Surgery · doi:10.1381/096089204323093345 · Cited by 461
Cesari, M., Pahor, M., & Incalzi, R. A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00171.x · Cited by 448
Inflamed Adipose Tissue: A Culprit Underlying the Metabolic Syndrome and Atherosclerosis
Gustafson, B., Hammarstedt, A., Andersson, C. X., & Smith, U. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147835 · Cited by 436
Sakkinen, P. A., Wahl, P., Cushman, M., Lewis, M. R., & Tracy, R. P. (2000) · American Journal of Epidemiology · doi:10.1093/aje/152.10.897 · Cited by 420
Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study
Pankow, J. S., Folsom, A. R., Cushman, M., Borecki, I. B., Hopkins, P. N., Eckfeldt, J. H., & Tracy, R. P. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00586-4 · Cited by 375
Konstantinides, S., Schäfer, K., Koschnick, S., & Loskutoff, D. J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13143 · Cited by 373
Self-citationThe plasminogen activator system: biology and regulation
Irigoyen, J. P., Muñoz-Cánoves, P., Montero, L., Koziczak, M., & Nagamine, Y. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000615 · Cited by 368
Peroxisome proliferator‐activated receptors in the cardiovascular system
Bishop‐Bailey, D. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703149 · Cited by 363
Marx, N., Bourcier, T., Sukhova, G. K., Libby, P., & Plutzky, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.546 · Cited by 362
Darvall, K. A. L., Sam, R. C., Silverman, S. H., Bradbury, A. W., & Adam, D. J. (2007) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2006.10.006 · Cited by 334
Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-positive Monocytes in Mice
Takahashi, K., Mizuarai, S., Araki, H., Mashiko, S., Ishihara, A., Kanatani, A., Itadani, H., & Kotani, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309895200 · Cited by 327
The mesentery: structure, function, and role in disease
Coffey, J. C., & O'Leary, D. P. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30026-7 · Cited by 319
The secretory function of adipocytes in the physiology of white adipose tissue
Wang, P., Mariman, E., Renes, J., & Keijer, J. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21386 · Cited by 318
Conjugated linoleic acid supplementation in humans—metabolic effects
Smedman, A., & Vessby, B. (2001) · Lipids · doi:10.1007/s11745-001-0784-7 · Cited by 305
Yang, G., Badeanlou, L., Bielawski, J., Roberts, A. J., Hannun, Y. A., & Samad, F. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.91014.2008 · Cited by 295
Self-citationObesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1
Skurk, T., & Hauner, H. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802778 · Cited by 297
Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease
Dellas, C., & Loskutoff, D. J. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0033 · Cited by 285
Self-citationMaquoi, E., Munaut, C., Colige, A., Collen, D., & Lijnen, H. R. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1093 · Cited by 271
Hedgehog signaling plays a conserved role in inhibiting fat formation
Suh, J. M., Gao, X., McKay, J., McKay, R., Salo, Z., & Graff, J. M. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2005.11.012 · Cited by 271
Fat as an Endocrine Organ: Relationship to the Metabolic Syndrome
Hutley, L., & Prins, J. B. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200512000-00005 · Cited by 262
Subcutaneous fat in normal and diseased states
Avram, M. M., Avram, A. S., & James, W. D. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.06.022 · Cited by 261
Eckel, R. H., Barouch, W. W., & Ershow, A. G. (2002) · Circulation · doi:10.1161/01.cir.0000017823.53114.4c · Cited by 258
Hyperglycemia-induced Production of Acute Phase Reactants in Adipose Tissue
Lin, Y., Rajala, M. W., Berger, J. P., Moller, D. E., Barzilai, N., & Scherer, P. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107101200 · Cited by 254
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243
Samad, F., Uysal, K. T., Wiesbrock, S. M., Pandey, M., Hotamisligil, G. S., & Loskutoff, D. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6902 · Cited by 226
Self-citationEffects of Lifestyle on Hemostasis, Fibrinolysis, and Platelet Reactivity: A Systematic Review
Lee, K. W., & Lip, G. Y. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.19.2368 · Cited by 217
“Recent evidence has shown that elevated plasma PAI-1 activity seen in obese individuals may be caused by increased PAI-1 release from visceral adipose tissue.(122,123) However, a liposuction procedure that removes visceral adipose tissue and achieves a weight reduction of 5% after 3 months without change in lifestyle…”
BackgroundHigh protein intake reduces intrahepatocellular lipid deposition in humans
Bortolotti, M., Kreis, R., Debard, C., Cariou, B., Faeh, D., Chetiveaux, M., Ith, M., Vermathen, P., Stefanoni, N., Lê, K.-A., et al. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27296 · Cited by 146
Bastard, J.-P., Vidal, H., Jardel, C., Bruckert, E., Robin, D., Vallier, P., Blondy, P., Turpin, G., Forest, C., & Hainque, B. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801087 · Cited by 35
Metadata
- Authors
- Loskutoff, D. J., & Samad, F.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1998-01
- Volume
- 18
- Issue
- 1
- Pages
- 1-6
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2136961309
- Cited by
- 264
- References
- 34
- FWCI
- 19.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.